1. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.
- Author
-
Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M, Apperley JF, Szydlo R, Desai R, Kozlowski K, Paliompeis C, Latham V, Foroni L, Molimard M, Reid A, Rezvani K, de Lavallade H, Guallar C, Goldman J, and Khorashad JS
- Subjects
- ATP Binding Cassette Transporter, Subfamily B, ATP Binding Cassette Transporter, Subfamily B, Member 1 genetics, Adult, Aged, Aged, 80 and over, Antineoplastic Agents pharmacokinetics, Benzamides, Drug Monitoring instrumentation, Female, Fusion Proteins, bcr-abl genetics, Humans, Imatinib Mesylate, Kaplan-Meier Estimate, Leukemia, Myelogenous, Chronic, BCR-ABL Positive genetics, Logistic Models, Male, Micro-Electrical-Mechanical Systems instrumentation, Middle Aged, Mutation, Octamer Transcription Factor-1 genetics, Piperazines pharmacokinetics, Polymorphism, Genetic, Proportional Hazards Models, Protein Kinase Inhibitors pharmacokinetics, Pyrimidines pharmacokinetics, RNA, Messenger metabolism, Risk Assessment, Risk Factors, Time Factors, Treatment Outcome, Young Adult, Antineoplastic Agents therapeutic use, Cytogenetic Analysis, Gene Expression Regulation, Leukemic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Medication Adherence, Piperazines therapeutic use, Protein Kinase Inhibitors therapeutic use, Pyrimidines therapeutic use
- Abstract
Purpose: There is a considerable variability in the level of molecular responses achieved with imatinib therapy in patients with chronic myeloid leukemia (CML). These differences could result from variable therapy adherence., Methods: Eighty-seven patients with chronic-phase CML treated with imatinib 400 mg/d for a median of 59.7 months (range, 25 to 104 months) who had achieved complete cytogenetic response had adherence monitored during a 3-month period by using a microelectronic monitoring device. Adherence was correlated with levels of molecular response. Other factors that could influence outcome were also analyzed., Results: Median adherence rate was 98% (range, 24% to 104%). Twenty-three patients (26.4%) had adherence
- Published
- 2010
- Full Text
- View/download PDF